HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (ophthalmology) as AbbVie.

Regulatory Analysis

Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.

Supporting Context

Therapeutic area
Ophthalmology · Gene Therapy
Sub-indication
Ophthalmology

Related signal: AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy

Source

View source document

Related Signal

Open signal — AbbVie Initiates Phase 2b/3 Trial of Surabgene Lomparvovec for Diabetic Retinopathy
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.